Predictive Oncology Inc. Q3 FY2023 earnings call

• Collaborated with Cancer Research Horizons in March 2023 to use AI drug discovery platform PEDAL to evaluate CRH preclinical glutaminase inhibitor drug compounds, provided initial results which is a milestone, and this could lead to development/commercialization milestones and sales royalties.
• Successfully completed a multiyear retrospective study with UPMC Magee-Women’s Hospital to build multi-omic machine learning models for ovarian cancer survival prediction, data to be presented in 2024, and there's opportunity to further utilize cohorts.
• Partnered with Cvergenx in February 2023 to develop genomics-based precision radiation therapy and drug discovery, evaluated models, submitted proposals to NASA and NIH, and collaboration drives data set expansion for commercialization.
• Developed a novel formulation for a protein drug candidate for an international pharma company, enabling toxicology studies.
• Collaborating with FluGen on a next-gen vaccine for respiratory disease, Phase IIb grant submitted to NIH.
• Met with 40 pharma companies at BIO-Europe, some interested in formulation services, endotoxin product, and HFC platform.
• Have an active biologics business providing formulation development and quality control testing on a fee-for-service basis.
• Created a Business Advisory Board with Dr. Bernard A. Harris, Jr. and Andrew Einhorn, seeking more diverse candidates.

In Q3 2023, revenue was $715,000 compared to $456,000 in Q3 2022. Gross margin in Q3 2023 was 85% vs. 76% in Q3 2022. Cash and cash equivalents at September 30, 2023 were $11.9 million compared to $22.1 million at December 31, 2022. Stockholders' equity at September 30, 2023 was $11.7 million vs. $21.8 million at December 31, 2022. The company has no long-term debt, and the balance sheet is strong.

• Anticipate more collaborations and partnerships with world's leading drug developers and research/academic institutions in coming quarters.
• Be at the forefront of AI and early drug discovery, playing an important role in oncology drug discovery, benefiting patients and creating enduring value for shareholders.

• Forward-looking statements are subject to substantial risks, uncertainties and assumptions about operations and investments. Actual future performance may materially differ from contemplated by forward-looking statements due to various factors including those discussed in SEC filings' Risk Factors.

Q: A: Q: A: